Neuss

• A study to see the effect of NNC0194-0499 alone or in combination with semaglutide on blood sugar control in people living with type 1 diabe … Ended recruitment
  2024-519533-38-00 3 2025-06-24 Diabetes mellitus type 1
• Safety and immunogenicity of an investigational Pentavalent Meningococcal ABCYW vaccine against meningococcal disease in children, toddlers, … Ended recruitment
  2023-510465-10-00 4 2025-03-10 Meningococcal immunization
• Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squam … Ended recruitment
  2023-507448-36-00 5 2024-02-16 Non-small Cell Lung Cancer
• A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokine … Ended recruitment
  2023-504215-32-00 9 2023-09-28 Overweight and obesity
• A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L … Ended recruitment
  2024-515047-31-00 5 2023-08-28 Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
• Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit … Ended recruitment
  2024-511209-49-00 6 2022-04-26 Patients with hormone receptor positive HER2 negative locally advanced
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell … Ended recruitment
  2023-503591-25-00 5 2020-06-09 Non-small cell lung cancer
• A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-sta … Halted
  2025-522551-25-00 3 2026-01-14 Type 2 Diabetes Mellitus
• A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinet … Halted
  2024-514744-91-00 3 2024-09-16 Obesity/overweight (healthy subjects)
• A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes Ended
  2025-521593-33-00 3 2025-12-03 Diabetes type 1
• A Trial to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR33 Compared with Insulin Degludec at stea … Ended
  2025-523052-32-00 3 2025-10-17 Type 1 diabetes Mellitus
• Vonafexor in Impaired Renal Function and Suspected MASH Ended
  2023-509192-16-00 4 2025-07-01 Impaired renal function and suspected MASH
• A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump. Ended
  2024-520230-29-00 3 2025-07-01 Diabetes mellitus type 2
• Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2D Ended
  2023-508054-25-01 3 2025-02-26 Type 2 diabetes
• A study to test how insulin NNC0471-0119 H works in the body in participants with type 1 diabetes when given by an insulin pump. Ended
  2024-513472-18-00 3 2025-01-23 Diabetes mellitus type 1
• A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide Ended
  2024-516901-21-00 3 2024-12-23 Weight management
• A research study of a new medicine NNC0363-1063 in healthy participants and participants with type 1 diabetes Ended
  2024-511808-17-00 1 2024-10-31 Type 1 diabetes mellitus
• CK-0045 proof-of-concept study Ended
  2024-514191-41-00 4 2024-09-16 Type 2 diabetes and Obesity
• A Phase 2 Parallel Group Study in Adults with Type 2 Diabetes to evaluate Efficacy and Safety of GL0034 Ended
  2024-513279-41-00 4 2024-09-06 Type 2 diabetes mellitus
• Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers Ended
  2023-505762-29-00 5 2024-08-09 Virus diseases
• Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes. Ended
  2023-509483-20-00 3 2024-04-26 Type 2 diabetes
• A research study of a new medicine (NNC0650-0013) in healthy men Ended
  2023-506134-79-00 1 2024-01-23 Weight management, Diabetes mellitus type 2; healthy subjects
• A study to assess the pharmacokinetics, and glucodynamics of LY3209590 in participants with type 2 diabetes Ended
  2023-508008-39-00 3 2023-12-05 Type 2 Diabetes Mellitus
• Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113‑6856 in healthy participants, including a subset of … Ended
  2023-503891-26-00 3 2023-09-29 Type 2 diabetes

Showing 25–48 of 54 trials